The Impact CPA technology enables testing of platelet adhesion and aggregation under arterial flow conditions to screen for hemostasis abnormalities and assess response to aspirin and clopidogrel.
Answers are grounded in this paper and cite their sources.
May enable flow-based platelet testing for hemostasis screening; leaves open clinical adoption pending prospective validation.
The Impact [cone and plate(let) analyzer (CPA) Technology]is testing whole blood platelet adhesion and aggregation under arterial flow conditions. The adhered platelets are stained and the percentage of surface covered (SC) by the stained objects and the average size (AS) of the objects are determined by image analyzer. The system allows screening of congenital primary hemostasis abnormalities, including adhesion as well as aggregation defects. The observation that exposure of blood to suboptimal concentrations of platelet agonists for 1 min prior to the Impact test causes platelet adhesion refractoriness led to the development of Impact aggregation tests and of specific tests for the determination of platelet response to aspirin and clopidogrel.
No takes yet. Share an insight, caveat, or question.
Savion et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: